The orexin neurotransmitter system as a target for medication development for opioid use disorder

Neuropsychopharmacology. 2024 Jan;49(1):329-330. doi: 10.1038/s41386-023-01679-0.

Authors

A S Huhn¹, K E Dunn²

Affiliations

¹ Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224, USA.
² Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224, USA. kdunn9@jhmi.edu.

PMID: 37491670
PMCID: PMC10700298 (available on 2025-01-01)
DOI: 10.1038/s41386-023-01679-0

No abstract available

Publication types

News

MeSH terms

Drug Development
Humans
Neurotransmitter Agents
Opioid-Related Disorders* / drug therapy
Orexin Receptors / therapeutic use
Orexins

Substances

Orexins
Neurotransmitter Agents
Orexin Receptors

Grants and funding

UH3 DA048734/DA/NIDA NIH HHS/United States